Peptide Research Library
A curated collection of published research on the peptides studied for companion animal wellness. Every study below links to its primary source on PubMed or NCBI. Findings in preclinical models do not establish efficacy or outcomes in pets — this library is intended as educational context for the science behind our protocols.
Important: The studies linked below are published preclinical and laboratory research. Most have been conducted in rodent models or in vitro systems. They are not clinical trials in companion animals and do not constitute evidence of efficacy in dogs or cats. Always consult a licensed veterinarian before considering peptide therapy for your pet.
BPC-157 Research
Body Protection Compound-157 (BPC-157) is a 15-amino-acid synthetic peptide derived from a protective protein in human gastric juice. The published research base spans gastrointestinal protection, tendon and ligament biology, vascular signaling, and tissue repair — primarily in rodent models, with a small but growing body of clinical case reports in companion animals.
Canine Clinical Case Report
Integrative Management of Canine Stifle Injuries — BPC-157 and TB-500 Protocol
Journal of the American Holistic Veterinary Medical Association · Vol. 77 · Winter 2024
A peer-reviewed canine case report published in AHVMA's journal documenting the use of BPC-157 with TB-500 in a dog with a stifle injury. Protocol used oral administration at approximately 6.5 mcg/kg of each peptide, three sprays daily for four weeks, alongside laser therapy and TCVM herbal support. The dog showed clinical improvement and was fully weight-bearing by the third laser session. Notable as one of the few peer-reviewed clinical case reports involving BPC-157 in companion animals.
AHVMA Vol. 77 · View Full Paper (PDF) →
Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs
He L, et al. · Frontiers in Pharmacology · 2022
One of the few BPC-157 studies that includes canine data. Established pharmacokinetic profile, elimination half-life, and bioavailability in beagle dogs. Intramuscular bioavailability ~45-51% in beagles vs ~14-19% in rats.
PMC9794587 · View on PubMed →
Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Sikiric P, et al. · Current Pharmaceutical Design · 2018
Comprehensive review of BPC-157's GI protective effects across decades of preclinical research. Covers gastric ulcer healing, intestinal anastomosis, vascular and neural mechanisms.
PMID: 29486690 · View on PubMed →
BPC 157 and Standard Angiogenic Growth Factors: Interactions
Seiwerth S, et al. · 2018
Examined how BPC-157 interacts with VEGF, EGF, and FGF pathways during tissue healing in rodent models. Found synergistic activity rather than replacement of natural healing processes.
PMID: 29998800 · View on PubMed →
Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review
Krzywik J, et al. · Pharmaceuticals (MDPI) · 2025
Recent comprehensive literature review covering BPC-157's preclinical evidence across gastrointestinal, musculoskeletal, vascular, and neural applications. Includes patent landscape and regulatory considerations.
MDPI · Open Access Review →
Pentadecapeptide BPC 157 enhances tendon healing and growth hormone receptor expression
Chang CH, et al. · Molecules · 2011
Demonstrated BPC-157's effect on growth hormone receptor expression in tendon fibroblasts, with implications for tendon-to-bone healing models in rats.
PMID: 21195720 · View on PubMed →
KPV Research
KPV (Lys-Pro-Val) is a naturally derived tripeptide from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH). Research has examined its role in NF-κB inflammatory pathway modulation, particularly in models of colitis, inflammatory bowel disease, and atopic skin conditions.
KPV (a tetrapeptide of α-MSH) inhibits NF-κB and mast cell activation
Getting SJ, et al. · Journal of Immunology · 1999
Early foundational study demonstrating KPV's anti-inflammatory mechanism through NF-κB pathway inhibition and mast cell modulation. Widely cited basis for KPV's role in inflammatory and allergic conditions.
PMID: 10570283 · View on PubMed →
Tripeptide KPV in mouse colitis model: anti-inflammatory effects
Dalmasso G, et al. · 2008
Controlled mouse colitis study demonstrating KPV's reduction in inflammation markers via NF-κB inhibition. Frequently cited preclinical evidence for KPV's role in inflammatory bowel applications.
PMC2431115 · View on PubMed Central →
Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease
Rodrigues JM, et al. · 2025
Recent review of host defense peptides including KPV-related compounds as therapeutic strategies for inflammatory bowel conditions.
Search PubMed →
α-MSH and KPV in melanocyte autophagy and vitiligo
Zeng K, et al. · Cell Death & Differentiation · 2026
Recent research on melanocyte biology and the alpha-MSH/KPV signaling axis, with implications for inflammatory skin conditions.
PMID: 40935835 · View on PubMed →
GHK-Cu Research
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide. The research base spans collagen synthesis, wound healing, gene expression modulation, and skin barrier biology. GHK-Cu is one of the more extensively studied peptides for skin and connective tissue applications.
The human tri-peptide GHK and tissue remodeling
Pickart L, Margolina A · Biochimica et Biophysica Acta · 2015
Comprehensive review of GHK-Cu's effects on tissue remodeling, gene expression (modulating ~31% of human genes by ≥50% expression change), collagen synthesis, and extracellular matrix biology.
Search PubMed →
GHK-Cu effects in irradiated human dermal fibroblasts
Abdulghani AA, et al. · 1999
Demonstrated GHK-Cu's stimulation of VEGF and bFGF expression in irradiated human dermal fibroblasts at nanomolar concentrations. Foundational reference for skin barrier and wound healing applications.
Search PubMed →
GHK-Cu and skin barrier repair
Pickart L, et al. · International Journal of Molecular Sciences · 2017-2018
Reviews of GHK-Cu's role in skin barrier integrity, with applications in regeneration and recovery from skin damage.
Search PubMed →
Copper tripeptide in canine wound healing and regeneration
Veterinary research literature
GHK-Cu has been specifically studied in dogs in research on wound healing, hair follicle regeneration, gastrointestinal tract repair, and bone healing — one of the few peptides with direct canine research data.
Search PubMed →
Peptide Therapeutics: Broader Research Context
Selected reviews and analyses on peptide therapeutics generally, which provide context for the regulatory, pharmacokinetic, and translational considerations relevant to peptide use in companion animals.
Therapeutic peptides: Current applications and future directions
Wang L, et al. · Signal Transduction and Targeted Therapy · 2022
Comprehensive review of peptide therapeutics in clinical and research applications, covering pharmacokinetics, delivery challenges, and regulatory pathways.
Search PubMed →
Strategies for improving peptide stability and delivery
Al Musaimi O, et al. · Pharmaceuticals · 2022
Review of peptide formulation, stability, and bioavailability considerations relevant to oral and parenteral peptide therapy.
Search PubMed →
FDA Statement: These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. None of the peptides referenced are FDA-approved for use in animals. Always consult with a licensed veterinarian before introducing any peptide-based supplement to your pet.
Considering peptide wellness for your pet?
Every Companion Peptide protocol is reviewed by a licensed integrative veterinarian. Tell us about your pet to get started.
Get Started →